Physician profile
Amelia E Pitha
NPI 1275179137
$1,247.00
in general payments reported to CMS, 2019-2025
21 companies · $384 in 2025
The $384 reported for 2025 was more than what a typical Acute Care (Nurse Practitioner) provider received nationally (typical 2025 total: $151).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $278 · 2024: $585 · 2025: $384.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,220 · Education: $27.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,220.00 |
| Education | $27.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $290.04 | 2023-2024 | Azure Xt Dr Mri Surescan, Micra, Selectsecure |
| Merck Sharp & Dohme LLC | $164.40 | 2024-2025 | Verquvo, Capvaxive |
| Pfizer INC. | $85.24 | 2023-2025 | |
| Janssen Pharmaceuticals, INC | $78.72 | 2023-2024 | Xarelto |
| Boehringer Ingelheim Pharmaceuticals, INC. | $66.65 | 2023-2024 | Jardiance |
| Novo Nordisk INC | $61.31 | 2024-2025 | Wegovy |
| Kestra Medical Technology Services, INC. | $52.76 | 2024-2025 | Assure Wcd |
| Boston Scientific Corporation | $51.10 | 2024-2025 | Watchman Access System |
| Chiesi USA, INC. | $49.92 | 2023-2024 | Kengreal |
| Novartis Pharmaceuticals Corporation | $48.65 | 2025 | |
| Scpharmaceuticals INC. | $45.08 | 2025 | |
| Bridgebio Pharma, INC. | $39.83 | 2025 | Attruby |
| E.R. Squibb & Sons, L.L.C. | $39.05 | 2023-2024 | Eliquis |
| Teleflex LLC | $36.78 | 2024 | Trapliner |
| Sanofi-Aventis U.S. LLC | $23.53 | 2024 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Resmed Corp | $22.07 | 2024 | |
| Bayer Healthcare Pharmaceuticals INC. | $20.53 | 2025 | |
| Recor Medical INC | $19.35 | 2025 | Paradise Ultrasound Renal Denervation System |
| Cvrx, INC. | $17.87 | 2024 | Barostim Neo System |
| Esperion Therapeutics, INC. | $17.47 | 2024 | Nexletol |
| Astrazeneca Pharmaceuticals LP | $16.65 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amelia Pitha listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.